Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): Consensus statement

Mayo Clinic Proceedings

Volumn 82, Issue 3, 2007, Pages 323-341

  Dispenzieri, Angela ^a   Rajkumar, S Vincent ^a   Gertz, Morie A ^a   Fonseca, Rafael ^b   Lacy, Martha Q ^a   Bergsagel, P Leif ^b   Kyle, Robert A ^a   Greipp, Philip R ^a   Witzig, Thomas E ^a   Reeder, Craig B ^b   Lust, John A ^a   Russell, Stephen J ^a   Hayman, Suzanne R ^a   Roy, Vivek ^c   Kumar, Shaji ^a   Zeldenrust, Steven R ^a   Dalton, Robert J ^d   Stewart, A Keith ^b  

^a Mayo Clinic College of Medicine   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

^d ALBERT LEA EYE CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; BORTEZOMIB; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; ERYTHROPOIETIN; GLUCOCORTICOID; LENALIDOMIDE; MELPHALAN; METHYLPREDNISOLONE; NITROSOUREA; PREDNISONE; THALIDOMIDE; VINCRISTINE; WARFARIN;

ALOPECIA; BONE MARROW TRANSPLANTATION; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CARDIOTOXICITY; CELL LABELING; COMBINATION CHEMOTHERAPY; CYTOGENETICS; DEATH; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; INFECTION; LOW DRUG DOSE; LUNG EMBOLISM; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; ORTHOSTATIC HYPOTENSION; PERIPHERAL NEUROPATHY; PLASMA CELL; PNEUMONIA; REVIEW; RISK; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT INDICATION; VOMITING;

EID: 33847369790     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/82.3.323     Document Type: Article

References (207)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Kyle RA. Long-term survival in multiple myeloma. N Engl J Med. 1983;308:314-316.
3. Long-term survival in multiple myeloma: a Finnish Leukaemia Group study. Br J Haematol. 1999;105:942-947.
4. Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842-854.
5. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma [published correction appears in J Clin Oncol. 2005 Sep 1;23:6281]. J Clin Oncol. 2005 May 20;23:3412-3420. Epub 2005 Apr 4.
6. Stewart AK, Bergsagel PL, Greipp PR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007 Jan 18; [Epub ahead of print].
7. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C, Groupe Francais de Cytogenetique Hematologique. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001;98:2229-2238.
8. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003 Jun 1;101:4569-4575. Epub 2003 Feb 6.
9. Konigsberg R, Zojer N, Ackermann J, et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol. 2000;18:804-812.
10. Tricot G, Barlogie B, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 1 Iq and not with other karyotype abnormalities. Blood. 1995;86:4250-4256.
11. 2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood. 2001;97:1566-1571.
12. Fassas AB, Spencer T, Sawyer J, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol. 2002;118:1041-1047.
13. Chiecchio L, Protheroe RK, Ibrahim AH, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia. 2006 Sep;20:1610-1617. Epub 2006 Jul 6.
14. Agnelli L, Bicciato S, Mattioli M, et al. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. J Clin Oncol. 2005 Oct 10;23:7296-7306. Epub 2005 Aug 29.
15. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23:6333-6338.
16. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006 Sep 15;108:2020-2028. Epub 2006 May 25.
17. Fonseca R, Harrington D, Blood E, et al, ECOG Myeloma Group. A molecular classification of multiple myeloma (MM), based on cytogenetic abnormalities detected by interphase FISH, is powerful in identifying discrete groups of patients with dissimilar prognosis [abstract]. Blood. 2001;98:733a-734a.
18. Drach J, Angerler J, Schuster J, et al. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood. 1995;86:3915-3921.
19. Zandecki M, Lai JL, Facon T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol. 1996;94:217-227.
20. Dao DD, Sawyer JR, Epstein J, Hoover RG, Barlogie B, Tricot G. Deletion of the retinoblastoma gene in multiple myeloma. Leukemia. 1994;8:1280-1284.
21. Dewald GW, Kyle RA, Hicks GA, Greipp PR. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood. 1985;66:380-390.
22. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet. 1995;82:41-49.
23. Smadja NV, Fruchart C, Isnard F, et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia. 1998;12:960-969.
24. Rajkumar S, Fonseca R, Lacy M, et al. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Bone Marrow Transplant. 1999;24:497-503.
25. Rajkumar SV, Fonseca R, Dewald GW, et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet. 1999;113:73-77.
26. Zojer N, Konigsberg R, Ackermann J, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood. 2000;95:1925-1930.
27. Barlogie B, Alexanian R, Dixon D, Smith L, Smallwood L, Delasalle K. Prognostic implications of tumor cell DNA and RNA content in multiple myeloma. Blood. 1985;66:338-341.
28. Morgan RJ Jr, Gonchoroff NJ, Katzmann JA, Witzig TE, Kyle RA, Greipp PR. Detection of hypodiploidy using multi-parameter flow cytometric analysis: a prognostic indicator in multiple myeloma. Am J Hematol. 1989;30:195-200.
29. Chng WJ, Ketterling RP, Fonseca R. Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma. Genes Chromosomes Cancer. 2006;45:1111-1120.
30. Gould J, Alexanian R, Goodacre A, Pathak S, Hecht B, Barlogie B. Plasma cell karyotype in multiple myeloma. Blood. 1988;71:453-456.
31. Seong C, Delasalle K, Hayes K, et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol. 1998;101:189-194.
32. Debes-Marun CS, Dewald GW, Bryant S, et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia. 2003;17:427-436.
33. Shaughnessy J Jr, Tian E, Sawyer J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol. 2003;120:44-52.
34. Fonseca R, Debes-Marun CS, Picken EB, et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003 Oct 1;102:2562-2567. Epub 2003 Jun 12.
35. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93:1032-1037.
36. Drach J, Schuster J, Nowotny H, et al. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res. 1995;55:3854-3859.
37. Perez-Simon JA, Garcia-Sanz R, Tabernero MD, et al. Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. Blood. 1998;91:3366-3371.
38. Fonseca R, Harrington D, Oken MM, et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an Eastern Cooperative Oncology Group study. Cancer Res. 2002;62:715-720.
39. Chng WJ, Santana-Davila R, Van Wier SA, et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia. 2006;20:807-813.
40. Tricot G, Sawyer JR, Jagannath S, et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol. 1997;15:2659-2666.
41. Desikan R, Barlogie B, Sawyer J, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000;95:4008-4010.
42. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55-65.
43. Fonseca R, Oken MM, Harrington D, et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia. 2001;15:981-986.
44. Worel N, Greinix H, Ackermann J, et al. Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma. Ann Hematol. 2001;80:345-348.
45. Chesi M, Kuehl WM, Bergsagel PL. Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma. Ann Oncol. 2000;11(suppl):131-135.
46. Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32): evidence for a biologically defined unique subset of patients. Blood. 2002;99:3735-3741.
47. Shaughnessy J Jr, Gabrea A, Qi Y, et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood. 2001;98:217-223.
48. Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 1997;16:260-264.
49. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood. 1998;92:3025-3034.
50. Richelda R, Ronchetti D, Baldini L, et al. A novel chromosomal translocation t(4; 14)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood. 1997;90:4062-4070.
51. Avet-Loiseau H, Li JY, Facon T, et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res. 1998;58:5640-5645.
52. Fonseca R, Conte G, Greipp PR. Laboratory correlates in multiple myeloma: how useful for prognosis? Blood Rev. 2001;15:97-102.
53. Avet-Loiseau H, Li JY, Godon C, et al. P53 deletion is not a frequent event in multiple myeloma. Br J Haematol. 1999;106:717-719.
54. Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998;92:802-809.
55. Portier M, Moles JP, Mazars GR, et al. p53 and RAS gene mutations in multiple myeloma. Oncogene. 1992;7:2539-2543.
56. Corradini P, Inghirami G, Astolfi M, et al. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia. 1994;8:758-767.
57. Mazars G-R, Portier M, Zhang XG, et al. Mutations of the p53 gene in human myeloma cell lines. Oncogene. 1992;7:1015-1018.
58. Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood. 1993;81:128-135.
59. Preudhomme C, Facon T, Zandecki M, et al. Rare occurrence of P53 gene mutations in multiple myeloma. Br J Haematol. 1992;81:440-443.
60. 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood. 1988;72:219-223.
61. 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81:3382-3387.
62. Rajkumar SV, Kyle RA. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2005;80:1371-1382.
63. Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006;81:1047-1053.
64. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-757.
65. Kyle R, Remstein E, Therneau T, et al. The natural history of smoldering (asymptomatic) multiple myeloma [abstract]. Blood. 2005;106:949a. Abstract 3396.
66. Riccardi A, Ucci G, Luoni R, et al, Cooperative Group of Study and Treatment of Multiple Myeloma. Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Br J Cancer. 1994;70:1203-1210.
67. Riccardi A, Mora O, Tinelli C, et al, Cooperative Group of Study and Treatment of Multiple Myeloma. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Br J Cancer. 2000;82:1254-1260.
68. Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rodjer S, Westin J, Myeloma Group of Western Sweden. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I: a randomized study. Eur J Haematol. 1993;50:95-102.
69. Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc. 2006;81:693-703.
70. Weber D, Wang LM, Delasalle K, Smith T, Alexanian R. Risk factors for early progression of asymptomatic multiple myeloma [abstract]. Hematol J. 2003;4(suppl):S31.
71. Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol. 2002;20:1625-1634.
72. Witzig TE, Kyle RA, O'Fallon WM, Greipp PR. Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. Br J Haematol. 1994;87:266-272.
73. Xiong Y, Donovan KA, Kline MP, et al. Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. J Interferon Cytokine Res. 2006;26:83-95.
74. Treatment of myeloma: comparison of melphalan, chlorambucil, and azathioprine. Arch Intern Med. 1975;135:157-162.
75. Facon T, Mary J, Harousseau J, et al. Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma [abstract]. J Clin Oncol. 2006;24(suppl):1s. Abstract 1.
76. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol. 1998;16:3832-3842.
77. Facon T, Mary JY, Pegourie B, et al, Intergroupe Francophone du Myelome (IFM) group. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood. 2006 Feb 15;107:1292-1298. Epub 2005 Sep 20.
78. Palumbo A, Bringhen S, Caravita T, et al, Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825-831.
79. Facon T, Mary JY, Hulin C, et al. Major superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma [abstract]. Blood. 2005;106:230a. Abstract 780.
80. Ludwig H, Drach J, Tothova E, et al. Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: an interim analysis [abstract]. Blood. 2005;106:231a. Abstract 782.
81. Rajkumar SV, Hussein M, Catalane J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as initial therapy for newly diagnosed multiple myeloma [abstract]. J Clin Oncol. 2006;24(suppl):426s. Abstract 7517.
82. Dimopoulos MA, Anagnostopoulos A, Terpos E, et al, Greek Myeloma Study Group. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica. 2006;91:252-254.
83. Offidani M, Corvatta L, Piersantelli MN, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood. 2006 Oct 1;108:2159-2164. Epub 2006 Jun 8.
84. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006 Oct 1;108:2165-2172. Epub 2006 Jun 13.
85. Hussein MA, Baz R, Srkalovic G, et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc. 2006;81:889-895.
86. Klueppelberg U, Shapira I, Smith E, et al. Treatment of newly diagnosed, inner-city multiple myeloma patients with low-dose thalidomide in combination with dexamethasone and zoledronate: a phase II trial [abstract]. Blood. 2005;106:379b. Abstract 5180.
87. Palumbo A, Falco P, Benevolo G, et al. Oral lenalidomide plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma [abstract]. J Clin Oncol. 2006;24(suppl):426s. Abstract 7518.
88. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR, Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006 Jan 20;24:431-436. Epub 2005 Dec 19.
89. Rifkin RM, Gregory SA, Mohrbacher A, Hussein MA. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer. 2006;106:848-858.
90. Dimopoulos MA, Pouli A, Zervas K, et al, Greek Myeloma Study Group. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol. 2003;14:1039-1044.
91. Goldschmidt H, Sonneveld P, Breitkreuz I, et al. HOVON 50/GMMG-HD3-Trial: phase III study on the effect of thalidomide combined with high dose melphalan in myeloma patients up to 65 years [abstract]. Blood. 2005;106:128a. Abstract 424.
92. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021-1030.
93. Rajkumar SV, Dispenzieri A, Fonseca R, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia. 2001;15:1274-1276.
94. Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia. 2003;17:775-779.
95. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;2l:16-19.
96. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20:4319-4323.
97. Sidra G, Williams CD, Russell NH, Zaman S, Myers B, Byrne JL. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica. 2006;91:862-863.
98. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005 Dec 15;106:4050-4053. Epub 2005 Aug 23.
99. Niesvizky R, Jayabalan DS, Furst JR, et al. Clarithromycin. lenalidomide and dexamethasone combination therapy as primary treatment of multiple myeloma [abstract]. J Clin Oncol. 2006;24(suppl):433s. Abstract 7545.
100. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005;129:776-783.
101. Jagannath S, Durie B, Wolf J, et al. Bortezomib therapy alone and in combination and dexamathasone for patients with previously untreated multiple myeloma [abstract]. Blood. 2005;106:231a. Abstract 783.
102. Anderson K, Richardson P, Chanan-Khan A, et al. Single-agent bortezomib in previously untreated multiple myeloma (MM): results of a phase II multicenter study [abstract]. J Clin Oncol. 2006;24(suppl):423s. Abstract 7504.
103. Harousseau JL, Attal M, Coiteux V, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM phase II study [abstract]. J Clin Oncol. 2005;23(suppl):598s. Abstract 6653.
104. Wang M, Delasalle K, Giralt S, Alexanian R. Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy [abstract]. Blood. 2005;106:231a. Abstract 784.
105. Hussein MA, Wood L, Hsi E, et al. A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer. 2002;95:2160-2168.
106. Hassoun H, Reich L, Klimek VM, et al. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Haematol. 2006;132:155-161.
107. Zervas K, Dimopoulos MA, Hatzicharissi E, et al, Greek Myeloma Study Group. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol. 2004;15:134-138.
108. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005;129:755-762.
109. Popat R, Oakervee HE, Curry N, et al. Reduced dose PAD combination therapy (PS-341/bortezomib, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma [abstract]. Blood. 2005;106:717a-718a. Abstract 2554.
110. Badros A, Rapoport A, Goloubeva O, et al. Phase I trial of bortezomib (V) in combination with "DT-PACE": toxicity, stem cell collection and engraftment in newly diagnosed multiple myeloma (MM) patients (Pts) [abstract]. Blood. 2005;106:771a. Abstract 2747.
111. Barlogie B, Tricot G, Rasmussen E, et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood. 2006 Apr 1;107:2633-2638. Epub 2005 Dec 1.
112. Chang H, Trieu Y, Qi X, Xu W, Stewart KA, Reece D. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res. 2006 Sep 20; [Epub ahead of print].
113. Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007 Jan;21:151-157. Epub 2006 Nov 9.
114. Sagaster V, Ludwig H, Kaufmann H, et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia. 2007 Jan;21:164-168. Epub 2006 Nov 9.
115. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) wilh tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006 May 1;107:3474-3480. Epub 2006 Jan 5.
116. Moreau P, Hullin C, Garban F, et al, Intergroupe Francophone du Myelome group. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood. 2006 Jan 1;107:397-403. Epub 2005 Sep 6.
117. Kyle RA, Pierre RV, Bayrd ED. Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med. 1970;283:1121-1125.
118. Nordenson NG. Myelomatosis: a clinical review of 310 cases. Acta Med Scand Suppl. 1966;445:178-186.
119. Edwards GA, Zawadzki ZA. Extraosseous lesions in plasma cell myeloma: a report of six cases. Am J Med. 1967;43:194-205.
120. Gonzalez F, Trujillo JM, Alexanian R. Acute leukemia in multiple myeloma. Ann Intern Med. 1977;86:440-443.
121. Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB. The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med. 1979;301:743-748.
122. MacLennan IC, Kelly K, Crockson RA, Cooper EH, Cuzick J, Chapman C. Results of the MRC myelomatosis trials for patients entered since 1980. Hematol Oncol. 1988;6:145-158.
123. MacLennan IC, Cusick J, Medical Research Council Working Party on Leukaemia in Adults. Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Br J Cancer. 1985;52:153-158.
124. Remission maintenance therapy for multiple myeloma. Arch Intern Med. 1975;135:147-152.
125. Cohen HJ, Bartolucci AA, Forman WB, Silberman HR. Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment. J Clin Oncol. 1986;4:888-899.
126. Peest D, Deicher H, Coldewey R, Schmoll HJ, Schedel I. Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP. Eur J Cancer Clin Oncol. 1988;24:1061-1067.
127. Belch A, Shelley W, Bergsagel D, et al. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer. 1988;57:94-99.
128. Kildahl-Andersen O, Bjark P, Bondevik A, et al. Multiple myeloma in central and northern Norway 1981-1982: a follow-up study of a randomized clinical trial of 5-drug combination therapy versus standard therapy. Eur J Haematol. 1988;41:47-51.
129. Medical Research Council's Working Party on Leukaemia in Adults. Treatment comparisons in the third MRC myelomatosis trial. Br J Cancer. 1980;42:823-830.
130. Alexanian R, Gehan E, Haut A, Saiki J, Weick J. Unmaintained remissions in multiple myeloma. Blood. 1978;51:1005-1011.
131. Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood. 2002;99:3163-3168.
132. Alexanian R, Weber D, Dimopoulos M, Delasalle K, Smith TL. Randomized trial of α-interferon or dexamethasone as maintenance treatment for multiple myeloma. Am J Hematol. 2000;65:204-209.
133. Mandelli F, Avvisati G, Amadori S, et al. Maintenance treatment with recombinant Interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med. 1990;322:1430-1434.
134. Ludwig H, Fritz E. Interferon in multiple myeloma: summary of treatment results and clinical implications. Acta Oncol. 2000;39:815-821.
135. Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol. 2001;113:1020-1034.
136. Brenning G, Ahre A, Nilsson K. Correlation between in vitro and in vivo sensitivity to human leucocyte interferon in patients with multiple myeloma. Scand J Haematol. 1985;35:543-549.
137. Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood. 2005 Oct 15;106:2837-2840. Epub 2005 Jun 23.
138. Chang H, Sloan S, Li D, et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol. 2004;125:64-68.
139. Chang H, Qi C, Yi QL, Reece D, Stewart AK. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood. 2005 Jan 1;105:358-360. Epub 2004 Aug 31.
140. Attal M, Harousseau JL, Leyvraz S, et al, Inter-Groupe Francophone du Myelome (IFM). Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006 Nov 15;108:3289-3294. Epub 2006 Jul 27.
141. Stewart AK, Chen CI, Howson-Jan K, et al. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res. 2004;10:8170-8176.
142. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Greipp P. A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood. 2006;108:239a. Abstract 799.
143. Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006 Nov;91:1498-1505. Epub 2006 Oct 17.
144. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984;310:1353-1356.
145. Forgeson GV, Selby P, Lakhani S, et al. Infused vincristine and adria-mycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients. Br J Cancer. 1988;58:469-473.
146. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990;33:86-89.
147. Samson D, Gaminara E, Newland A, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet. 1989;2:882-885.
148. Attal M, Huguet F, Schlaifer D, et al. Intensive combined therapy for previously untreated aggressive myeloma. Blood. 1992;79:1130-1136.
149. Raje N, Powles R, Kulkarni S, et al. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br J Haematol. 1997;97:153-160.
150. Kars A, Celik I, Kansu E, et al. Maintenance therapy with alpha-interferon following first-line VAD in multiple myeloma. Eur J Haematol. 1997;59:100-104.
151. Anderson H, Scarffe JH, Ranson M, et al. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer. 1995;71:326-330.
152. Segeren CM, Sonneveld P, van der Holt B, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol. 1999;105:127-130.
153. Fossa A, Muer M, Kasper C, Welt A, Seeber S, Nowrousian MR. Bolus vincristine and epirubicin with cyclophosphamide and dexamethasone (VECD) as induction and salvage treatment in multiple myeloma. Leukemia. 1998;12:422-426.
154. Tsiara SN, Kapsali E, Christou L, Panteli A, Pritsivelis N, Bourantas KL. Administration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients: preliminary data. Eur J Haematol. 2000;65:118-122.
155. Salmon SE, Crowley JJ, Balcerzak SP, et al. Interferon versus Interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol. 1998;16:890-896.
156. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood. 1992;80:887-890.
157. Anagnostopoulos A, Aleman A, Williams P, et al. Autologous stem cell transplantation (ASCT) after nonmyelosuppressive induction therapy with dexamethasone alone is safe and effective for newly diagnosed multiple myeloma (MM) pts who receive high dose chemotherapy (HDC). Blood. 2001;98:683a (abstract 2858).
158. Kumar S, Lacy MQ, Dispenzieri A, et al. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant. 2004;34:485-490.
159. Dispenzieri A, Zhang L, Fonseca R, Vesole DH, Greipp PR. Single agent bortezomib is associated with a high response rate in patients with high risk myeloma: a phase II study from the Eastern Cooperative Oncology Group (E2A02) [abstract]. Blood. 2006;108:1006a. Abstract 3527.
160. Lacy M, Gertz M, Dispenzieri A, et al. Lenalidomide plus dexamethasone (rev/dex) in newly diagnosed myeloma: response to therapy, time to progression, and survival [abstract]. Blood. 2006;108:239a. Abstract 798.
161. Dimopoulos MA, Spencer A, Attal M, et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010) [abstract]. Blood. 2005;106:6a. Abstract 6.
162. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamathasone alone for relapsed or refractory multiple myeloma (MM): results of a North American phase III study (MM-009) [abstract]. J Clin Oncol. 2006;24(suppl):427s. Abstract 7521.
163. Rajkumar SV, Blood E. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 2006;354:2079-2080.
164. Gertz MA, Lacy MQ, Inwards DJ, et al. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Bone Marrow Transplant. 1999;23:221-226.
165. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood. 1995;85:588-596.
166. Goldschmidt H, Hegenbart U, Wallmeier M, Hohaus S, Haas R. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol. 1997;98:736-744.
167. Kroger N, Zeller W, Hassan HT, et al. Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone. Ann Hematol. 1998;76:257-262.
168. Attal M, Harousseau JL, Stoppa AM, et al, Intergroupe Francais du Myelome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91-97.
169. Lenhoff S, Hjorth M, Holmberg E, et al, Nordic Myeloma Study Group. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood. 2000;95:7-11.
170. Child JA, Morgan GJ, Davies FE, et al, Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875-1883.
171. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood. 2004 Nov 15;104:3052-3057. Epub 2004 Jul 20.
172. Fermand JP, Katsahian S, Divine M, et al, Group Myelome-Autogreffe. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005 Dec 20;23:9227-9233. Epub 2005 Nov 7.
173. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: upfront or rescue treatment? results of a multicenter sequential randomized clinical trial. Blood. 1998;92:3131-3136.
174. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321 [published correction appears in J Clin Oncol. 2006:24:2687]. J Clin Oncol. 2006 Feb 20;24:929-936. Epub 2006 Jan 23.
175. Blade J, Rosinol L, Sureda A, et al, Programa para el Estudio de la Terapeutica en Hemopatia Maligna (PETHEMA). High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood. 2005 Dec 1:106:3755-3759. Epub 2005 Aug 16.
176. Harousseau JL, Attal M. The role of stem cell transplantation in multiple myeloma. Blood Rev. 2002;16:245-253.
177. Sonneveld P, van der Holt B, Vellenga E, et al. Intensive versus double intensive therapy in untreated multiple myeloma: final analysis of the HOVON 24 trial [abstract]. Blood. 2005;106:715a. Abstract 2545.
178. Attal M, Harousseau JL, Facon T, et al, InterGroupe Francophone du Myelome. Single versus double autologous stem-cell transplantation for multiple myeloma [published correction appears in N Engl J Med. 2004;350:2628]. N Engl J Med. 2003;349:2495-2502.
179. Cavo M, Cellini C, Zamagni E, et al. Superiority of double over single autologous stem cell transplantation as first-line therapy for multiple myeloma [abstract]. Blood. 2004;104:155a. Abstract 536.
180. Harousseau JL, Moreau P, Attal M, Facon T, Avet-Loiseau H. Stem-cell transplantation in multiple myeloma. Best Pract Res Clin Haematol. 2005;18:603-618.
181. Fermand J-P, Marolleau J-P, Alberti C, et al, Myélome-Autogreffe. In single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34 enriched ABSC: preliminary results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM) [abstract]. Blood. 2001;98:815a. Abstract 3387.
182. Zangari M, Barlogie B, Hollmig K, et al. Marked activity of velcade plus thalidomide (V+T) in advanced and refractory multiple myeloma (MM) [abstract]. Blood. 2004;104:413a. Abstract 1480.
183. Teoh G, Tan D, Hwang W, Koh LP, Chuah C, Ng HJ. Addition of bortezomib to thalidomide, dexamethasone and zoledronic acid (VTD-Z regimen) significantly improves complete remission rates in patients with relapsed/refractory multiple myeloma [abstract]. J Clin Oncol. 2006;24(suppl):683s. Abstract 17537.
184. Martinelli G, Terragna C, Zamagni E, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol. 2000;18:2273-2281.
185. Corradini P, Cavo M, Lokhorst H, et al, Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood. 2003 Sep 1;102:1927-1929. Epub 2003 May 8.
186. Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood. 1996;88:2787-2793.
187. Cavo M, Bandini G, Benni M, et al. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. Bone Marrow Transplant. 1998;22:27-32.
188. Gahrton G, Tura S, Ljungman P, et al, European Group for Bone Marrow Transplantation. Allogeneic bone marrow transplantation in multiple myeloma. N Engl JMed. 1991;325:1267-1273.
189. Gahrton G, Tura S, Ljungman P, et al, European Group for Blood and Marrow Transplantation. An update of prognostic factors for allogeneic bone marrow transplantation in multiple myeloma using matched sibling donors. Stem Cells. 1995;13(suppl):122-125.
190. Kennedy GA, Butler J, Morton J, et al. Myeloablative allogeneic stem cell transplantation for advanced stage multiple myeloma: very long-term follow up of a single center experience. Clin Lab Haematol. 2006;28:189-197.
191. Crawley C, Lalancette M, Szydlo R, et al, Chromic Leukaemia Working Party of the EBMT. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood. 2005 Jun 1;105:4532-4539. Epub 2005 Feb 24.
192. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003 Nov 1;102:3447-3454. Epub 2003 Jul 10.
193. Kroger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood. 2002;100:755-760.
194. Kroger N. Autologous-allogeneic tandem stem cell transplantation in patients with multiple myeloma. Leuk Lymphoma. 2005;46:813-821.
195. Kroger N, Sayer HG, Schwerdtfeger R, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood. 2002 Dec 1;100:3919-3924. Epub 2002 Aug 8.
196. Chang H, Qi XY, Samiee S, et al. Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplant. 2005;36:793-796.
197. Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood. 1999;93:51-54.
198. Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions [published corrections appear in Blood. 2001;98:271 and 1653]. Blood. 2001;97:2574-2579.
199. San Miguel JF, Lahuerta JJ, Garcia-Sanz R, et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J. 2000;1:28-36.
200. Lee CK, Zangari M, Barlogie B, et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant. 2004;33:823-828.
201. Knudsen LM, Nielsen B, Gimsing P, Geisler C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol. 2005;75:27-33.
202. Cunningham D, Powles R, Malpas J, et al. A randomized trial of maintenance Interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol. 1998;102:495-502.
203. Bjorkstrand B, Svensson H, Goldschmidt H, et al. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2001;27:511-515.
204. Brinker BT, Waller EK, Leong T, et al. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer. 2006;106:2171-2180.
205. Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol. 2004;126:715-721.
206. Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 2005;80:1568-1574.
207. Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 2006;354:2079-2080.